Health Blueprint

Back to Longevity News

News summary

Rivus to present data on new oral weight-loss drug that targets fat while saving muscle

Source: Longevity Technology • Published: 21 Oct 2026, 08:36

Summarized by Masters of Longevity from Longevity Technology.

A preview of a scientific poster set presenting preclinical data on an experimental oral weight‑loss compound that reportedly preserves muscle while reducing fat, useful for readers tracking emerging obesity therapeutics.

Rivus to present data on new oral weight-loss drug that targets fat while saving muscle
Key Takeaways
  • Rivus will present preclinical rodent and nonhuman primate data for RV-8451 at ObesityWeek 2026.
  • Poster abstracts report RV-8451 outperformed orforglipron in obesity models and produced fat-selective weight loss.
  • RV-8451 reportedly reversed orforglipron-induced lean mass loss in a diet-induced obesity mouse model.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.